Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202

Go back to Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202
(NASDAQ: NERV) Delayed: 2.30 -0.1 (4.17%)
Previous Close $2.40    52 Week High $15.84 
Open $2.37    52 Week Low $3.45 
Day High $2.65    P/E N/A 
Day Low $2.25    EPS $0.00 
Volume 137,588